Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05982496 | 18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer(FESTA) | recruiting | Phase 2 | 119 | Università Vita-Salute San RaffaeleOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06309290 | Prehabilitation With Resistance-exercise Training for Breast Cancer Neoadjuvant Therapy(NEO STRONG) | recruiting | N/A | 68 | Universidad de La FronteraOTHER | 1 | Jun 12, 2026 |
| clinicaltrials |
| NCT06763328 | Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy | recruiting | Phase 3 | 80 | City of Hope Medical CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06974929 | A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer | recruiting | Phase 1 / Phase 2 | 80 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07273812 | Evaluating an AI-Based Mobile Application for Chemotherapy Support in Breast Cancer Patients(AI-ChemoApp) | recruiting | N/A | 130 | Dena h. Al-TameemiOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07441889 | HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006) | recruiting | Phase 1 / Phase 2 | 23 | University of VirginiaOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07646106 | THE-0504 in Patients With Solid Tumors | recruiting | Phase 1 | 30 | Thena Biotech S.r.l.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03936478 | Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer(MAPBI) | recruiting | Phase 2 | 30 | University of Wisconsin, MadisonOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05076760 | MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | recruiting | Phase 1 | 40 | Memgen, Inc.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05283330 | Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors | recruiting | Phase 1 | 48 | Orano Med Theranostics, SASINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05902507 | Magnetic Resonance Imaging in Radiotherapy for Breast Cancer(MIRROR) | recruiting | — | 20 | University of California, San FranciscoOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06224673 | ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer | recruiting | Phase 2 | 36 | Laura Huppert, MD, BAOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07339306 | A Novel Fluorescent Ductal Needle for Localization and Sampling of Micro Lesions in Breast Ducts | recruiting | N/A | 300 | The Fourth Affiliated Hospital of China Medical UniversityOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05403177 | Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)(MOHCCN-O) | recruiting | — | 500 | University Health Network, TorontoOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06771609 | Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer. | recruiting | Phase 2 | 150 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06981208 | ChatGPT & Surgeon Synergy: Redefining Breast Reconstruction Consultations for Enhanced Patient Engagement and Satisfaction | recruiting | N/A | 410 | Washington University School of MedicineOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07198724 | ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer(ERADICATE) | recruiting | Phase 1 / Phase 2 | 65 | Kristina A. FanucciOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | recruiting | Phase 1 | 40 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07608848 | First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer(DOTA-STR-17126) | recruiting | Early Phase 1 | 20 | Integrated Haematology and Oncology NetworkOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06085313 | Cancer Pain Management Using a Web-based Intervention(CAI) | recruiting | N/A | 300 | University of Texas at AustinOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06776861 | A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer | recruiting | — | 150 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07307664 | Increasing Germline Genetic Testing for Patients With Cancer(gLHS) | recruiting | N/A | 1,000 | Josh PetersonOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07635342 | Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer | recruiting | Phase 2 | 182 | Hebei Medical University Fourth HospitalOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07225114 | Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging | recruiting | Phase 2 | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT00451022 | Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies | recruiting | — | 750 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2026 | clinicaltrials |
| NCT02906943 | Ontario-wide Cancer TArgeted Nucleic Acid Evaluation(OCTANE) | recruiting | — | 10,000 | University Health Network, TorontoOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT03417115 | Breast Cancer Registry Platform(OPAL) | recruiting | — | 6,150 | iOMEDICO AGINDUSTRY | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04529044 | 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer | recruiting | Phase 2 | 10 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06240195 | Biomarkers of Efficacy and Tolerability of Sacituzumab-Govitecan in the Treatment of Patients With Triple-negative Breast Cancer in the Metastatic Phase: Prospective Multicenter Real-world Study(BIO-PROSA) | recruiting | — | 60 | Regina Elena Cancer InstituteOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06297265 | Manual Lymphatic Drainage Breast Massage in Breast Cancer Patients After Breast Conserving Surgery | recruiting | N/A | 50 | University of Southern CaliforniaOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04457895 | Evaluation of the Efficacy of a Physical Therapy-yoga-patient Educational Program for Breast Cancer Patients With Pain Due to Hormonal Therapy Treatment.(SKYPE2) | recruiting | N/A | 108 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04638725 | Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer(SIGHER) | recruiting | — | 9,000 | Centre Paul StraussOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05660083 | Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) | recruiting | Phase 2 | 36 | The Methodist Hospital Research InstituteOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05741164 | Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer | recruiting | Phase 2 | 37 | Emory UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07483307 | A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer | recruiting | Phase 2 | 176 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07518173 | A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer | recruiting | Phase 3 | 596 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07616440 | Pilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug Delivery System Combined With Neoadjuvant Therapy for HER2-Positive Breast Cancer | recruiting | N/A | 20 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT02772367 | Generation of Heart Muscle Cells From Blood or Skin Cells of Breast Cancer Patients | recruiting | — | 120 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07311993 | Phase 1 Study of CLR 125 in Triple Negative Breast Cancer | recruiting | Phase 1 | 60 | Cellectar Biosciences, Inc.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07622836 | A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer. | recruiting | N/A | 59 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07623577 | Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases | recruiting | Phase 2 | 24 | Fudan UniversityOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT03823144 | Intravital Microscopy in Human Solid Tumors | recruiting | N/A | 85 | Mayo ClinicOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06127979 | A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery | recruiting | N/A | 42 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06369831 | HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011(HERMIA) | recruiting | Phase 2 | 60 | Abscint NV/SAINDUSTRY | 2 | Jun 2, 2026 | clinicaltrials |
| NCT06783179 | Postoperative Outcomes and Patient Satisfaction With Mayo Clinic Florida Care Hotel After Mastectomy and Tissue Expander Placement | recruiting | — | 150 | Mayo ClinicOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06878547 | VisR Ultrasound for Noninvasively Interrogating Stromal Collagen Organization in Women as a Breast Cancer Biomarker: Evaluation of Anisotropy in Cancer Patients | recruiting | — | 250 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07454642 | AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors(FOCUS-01) | recruiting | Phase 1 | 174 | Avacta Life Sciences LtdINDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06388122 | DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients | recruiting | — | 100 | Mayo ClinicOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06498388 | Predicting Breast Cancer With the BRAVE System(BRAVE) | recruiting | — | 300 | Université de SherbrookeOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07076147 | Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer | recruiting | — | 150 | University of Southern CaliforniaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 12, 2026source: clinicaltrials